Market News & Trends
Croda Donates 1,000 Solar Panel Modules to Non-Profit Organizations
Croda International Plc, the name behind high-performance ingredients and technologies that are relied on by industries and consumers everywhere, has donated 1,000 SunPower solar panels…
Novigenix & Radbound University Medical Center Discover the First Blood-Based ImmunoTranscriptomic Biomarkers for Response to Anti-PD-1 Therapy
Novigenix SA recently announced release of the article Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer. Immune checkpoint inhibitors (ICIs) have become….
Genetron Health & IMPACT Therapeutics Announce Partnership to Drive Development of Synthetic Lethal Product Pipeline
Genetron Holdings Limited recently announced a partnership with IMPACT Therapeutics in which the two parties will cooperate together on research and development for synthetic lethal inhibitors that are based on….
Evelo Biosciences Announces Positive Phase 2 Clinical Data With EDP1815 in Psoriasis
Evelo Biosciences, Inc. recently announced positive data from its Phase 2 study evaluating EDP1815 versus placebo for the treatment of mild and moderate psoriasis. A statistically significant reduction in the….
Salarius Pharmaceuticals Receives $2.7 Million in Payment From the Cancer Prevention & Research Institute of Texas
Salarius Pharmaceuticals, Inc. recently announced the receipt of a $2.7-million payment under its existing contract with the Cancer Prevention and Research Institute of Texas (CPRIT).…
Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar & Vaginal Atrophy
Daré Bioscience, Inc. recently announced the initiation of a Phase 1/2 clinical study of DARE-VVA1, a novel intravaginal tamoxifen product being developed for the treatment…
Soligenix Announces Accelerated Publication Demonstrating Efficacy & Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates
Soligenix, Inc. recently announced publication of preclinical immunogenicity studies for CiVax (heat stable COVID-19 vaccine program) demonstrating durable broad-spectrum neutralizing antibody responses, including against the…
First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients With Ulcerative Proctitis & Ulcerative Proctosigmoiditis
First Wave BioPharma, Inc. recently announced it has begun screening patients for enrollment in a Phase 2b clinical trial investigating a topical formulation of FW-UP…
New BD Cell Analyzer Includes Spectral Analysis Capabilities
BD (Becton, Dickinson and Company) recently announced the launch of a spectral-enabled cell analyzer, expanding current cell analyzer capabilities to at least 34 parameters with…
BioXcel Therapeutics to Highlight Novel Approaches in AI-Based Drug Candidate Discovery & Development & Advances in Neuroscience Portfolio
BioXcel Therapeutics, Inc. recently hosted a virtual R&D Day that discussed new applications of the artificial intelligence ecosystem to augment and accelerate its drug candidate…
ESCP Models - Hepatitis C Medications (Part 1)
In a series of four articles earlier this year, the principles of the ESCP Analysis process were outlined with a few simple to understand examples. To better explain the application of the process, I have summarized the evolution of Hepatitis C (HCV) treatment from naked Interferon alpha treatment through to the latest….
BD Completes Study Investigating Performance of Glass Prefillable Syringes (PFS) in Deep Cold Storage
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, completed a preliminary study investigating the impact of deep cold storage (-20°C…
Credence MedSystems Secures $39.9 Million Financing to Enable Scaling of Innovative Drug Delivery & Connected Health Systems
Credence MedSystems, Inc. recently announced it has closed a funding round with gross proceeds of $39.9 million. Sources of funding include strategic investments from Novartis Pharma AG,….
Novartis Announces Collaboration on HARMONIA, a Phase 3, Head-to-Head Trial Evaluating Kisqali Versus Ibrance in Patients With HR+/HER2- Advanced Breast Cancer
Novartis recently announced a collaboration with SOLTI Innovative Cancer Research (SOLTI) on HARMONIA, an international, randomized, Phase 3, multicenter, open-label study of….
Clarus Therapeutics & McGill University Announce Exclusive Worldwide Licensing Agreement to Develop & Commercialize Technology to Treat Rare Conditions Associated With Coenzyme-Q10 (Ubiquinone) Deficiencies
Clarus Therapeutics Holdings, Inc. and McGill University recently announced a licensing agreement whereby Clarus will develop and commercialize McGill’s proprietary technology designed to treat….
FDA Approves Samsung Bioepis & Biogen’s BYOOVIZ (SB11), LUCENTIS Biosimilar (ranibizumab-nuna)
Samsung Bioepis Co., Ltd. and Biogen Inc. recently announced the US FDA has approved BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS (ranibizumab) for the treatment of neovascular….
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by US FDA for the Treatment of Relapsed or Recurrent Head & Neck Squamous Cell Carcinoma
AVEO Oncology recently announced the US FDA has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head…
Carrick Therapeutics Debuts Data for First-In-Class Oral CDK7 Inhibitor Samuraciclib
Carrick Therapeutics recently presented encouraging initial clinical data on samuraciclib (CT-7001), an oral and first-in-class inhibitor of CDK7, at the 2021 European Society of Medical…
Cue Biopharma Granted US Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101
Cue Biopharma, Inc. recently announced the issuance of two new United States Patents Nos. 11,117,945 and 11,104,712 from the United States Patent and Trademark Office.…
Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men With Metastatic Castration-Resistant Prostate Cancer
Veru Inc. recently announced that updated clinical data from the positive Phase 1b/2 study of sabizabulin (VERU-111) in 80 men with metastatic castration-resistant prostate cancer…
